| Name | Title | Contact Details |
|---|
Meadow Lawn Nursing Ctr is a Davenport, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MedData is a leading national provider of technology-enabled healthcare services designed to improve financial outcomes for hospitals by enhancing the patient experience and expanding their access to healthcare. The MedData suite of solutions includes a range of patient access & communications, revenue cycle management, and consulting & analytics services, including full service billing & coding, patient balances, eligibility & disability, third party liability and other complex A/R services, and mobile-first engagement and communication software for patients and providers. MedData has built this national presence by becoming experts at the state level. To date, we have handled billing for more than 200 million patients at our growing network of more than 2,000 hospital sites nationwide. For more than 36 years, MedData has solidified its leadership position by providing innovative solutions to the medical community and serving millions of patients across numerous medical specialties.
RedBrick is a health engagement technology company that helps employers reinvigorate their health & wellness programs.
Nueterra Capital is a private equity investment and advisory firm with an exclusive focus on healthcare. Leveraging a deep understanding of key industry drivers, Nueterra Capital invests in entrepreneurs with innovative minds, while providing professional expertise and back office resources to improve their bottom line performance and drive growth. Nueterra Capital has invested in hundreds of new ventures and continuously delivers the resources and strategic direction that allow our partners to advance and improve every aspect of healthcare.
TherOx, Inc. (TherOx) is a private, venture-financed medical device company based in Irvine, California, dedicated to elevating the standard of care for treatment of heart attack patients. A heart attack is caused when an artery in the heart becomes blocked. Current treatment of heart attack is to reestablish blood flow in the blocked artery as quickly as possible. Typically, this is done with a combination of medication and a percutaneous coronary intervention (PCI) which may include the placement of a (intracoronary) stent. PCI successfully restores blood flow, but damage to the patient’s heart remains. Blood flow in the microvasculature downstream from the blockage is compromised, and critical heart muscle tissue is damaged – or infarcted – due to oxygen deprivation brought on by the heart attack. The intent of SuperSaturated Oxygen (SSO2) Therapy from TherOx is to salvage damaged heart tissue by placing a high concentration of oxygen (~760 – 1,000 mmHg, or 5 – 7 times normal levels) into the patient’s blood plasma and delivering it directly to the area impacted by the heart attack. SSO2 Therapy serves as a complement to PCI and stenting. Immediately following the interventional procedure, proprietary technology from TherOx mixes a pre-specified concentration of “SuperOxygenated” saline solution with the patient’s blood to produce SuperOxygenated blood. The SuperOxygenated blood is then delivered through a catheter to the oxygen deficient tissue. Company research has confirmed in clinical studies that SuperSaturated Oxygen Therapy has the potential to reverse ischemia and may resuscitate tissue that may otherwise die. SSO2 Therapy circulates the patient`s own blood via the existing arterial access site used for the stenting procedure. Thus, no new access site is required. The TherOx DownStream System and DownStream Cartridge bear the CE Mark but are not available for commercial distribution in the EU at this time.